Trial Profile
A Randomised, Double Blind, Placebo-controlled, Multiple Dose Trial of Anti-IL-20 (109-0012) in Subjects With Rheumatoid Arthritis.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Fletikumab (Primary) ; Methotrexate
- Indications Rheumatoid arthritis
- Focus Therapeutic Use
- Sponsors Novo Nordisk
- 15 Jun 2013 Patient-reported outcomes presented at the 14th Annual Congress of the European League Against Rheumatism.
- 14 Nov 2012 Results presented at the 76th Annual Scientific Meeting of the American College of Rheumatology and the 47th Annual Meeting of the Association of Rheumatology and Health Professionals.
- 07 Nov 2012 Patient-reported pain and global disease activity presented at the 15th Annual European Conference of the International Society for Pharmacoeconomics and Outcomes Research.